Biogen (BIIB) Expected to Post Earnings on Wednesday

Posted by Brenda Bartman on Oct 26th, 2026

Biogen (NASDAQ:BIIB – Get Free Report) will likely be posting its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect Biogen to announce earnings of $1.97 per share and revenue of $2.63 billion for the quarter. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Investors may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:30 AM ET.

Biogen (NASDAQ:BIIB – Get Free Report) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. The company had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The firm’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the business earned $5.47 EPS. On average, analysts expect Biogen to post $12.29 EPS for the current fiscal year and $16.08 EPS for the next fiscal year.

Biogen Stock Performance

NASDAQ:BIIB opened at $250.69 on Monday. The company has a fifty day simple moving average of $223.60 and a two-hundred day simple moving average of $206.28. The company has a market cap of $37.04 billion, a price-to-earnings ratio of 44.37, a price-to-earnings-growth ratio of 2.99 and a beta of 0.09. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. Biogen has a 52 week low of $138.00 and a 52 week high of $254.41.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BIIB. BMO Capital Markets reiterated a “market perform” rating and issued a $220.00 price objective on shares of Biogen in a research note on Monday, October 12th. HC Wainwright boosted their target price on Biogen from $237.00 to $251.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Piper Sandler restated an “overweight” rating and set a $245.00 price target (up from $225.00) on shares of Biogen in a report on Thursday, September 3rd. Weiss Ratings raised Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, September 24th. Finally, Zacks Research raised Biogen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $241.89.

Read Our Latest Research Report on Biogen

About Biogen

(Get Free Report)

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.